Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

World-Renowned Neurologist and Bestselling Author Joins Forum Health’s Annual Integrative Medicine Summit

Forum Health

Forum Health, LLC, leading nationwide network of integrative and functional medicine providers, is thrilled to announce Dr. Dale Bredesen, a trailblazing neuroscientist and pioneer in Alzheimer's disease research, as the keynote speaker at the Forum Health Summit: Emerging Therapies in Integrative Medicine. Register for the Forum Health Summit here. With a career spanning over four decades, Dr. Bredesen has made groundbreaking contributions to neurological research, cognitive decline treatment, and Alzheimer's disease with his renowned Bredesen Protocol - the only Alzheimer’s treatment where the most patients have stabilized or improved. Dale Bredesen, MD: “I’m honored to be the keynote speaker at Forum Health’s annual summit. They are setting the stage to discuss the latest advancements in integrative medicine, bringing together the nation’s top providers, and providing me with the opportunity to share insights and collaborate with my colleagues to drive innovation and progress." Dr. Bredesen's presentation will delve into the latest advancements in Alzheimer's research and shed light on the importance of personalized medicine in combating cognitive decline. Attendees will receive invaluable insights into treatment modalities and preventative measures to preserve brain health. Phil Hagerman, Forum Health CEO: "We’re thrilled to have Dr. Bredesen join us this year. His unparalleled expertise and contributions to the medical community have been instrumental in advancing new treatment approaches to transform the landscape of Alzheimer's disease." The Forum Health Summit is a one-day conference that brings together the top thought leaders in integrative and functional medicine. Attendees receive the latest on emerging research, cutting-edge diagnosis, and treatment protocols for complex clinical cases from expert leaders in the field. The event will also feature presentations from industry experts including: Sahar Swidan, Pharm.D., BCPS, ABAAHP, FAARFM, FACA - President and CEO of NeuroPharm, and internationally renowned speaker on pain management and HRT Paul Anderson, MD - Recognized educator and clinician in integrative and naturopathic medicine focused on complex infecious, chronic and oncologic illnesses Thomas G. Gulliams, Ph.D. - Former VP of Ortho Molecular and expert in the therapeutic uses of dietary supplements Registration for this event is exclusive to licensed medical professionals, space limited and this event is expected to sell out. Register here. About Forum Health Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Forum Health Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

April 23, 2024 08:50 AM Eastern Daylight Time

Image

Wolfram and Classiq Integrate Advanced Quantum Software Tools into Mathematica

Classiq Technologies

In a landmark collaboration, Classiq, a leader in quantum computing software, and Wolfram Research, the leading computational software provider, announce a software partnership. This collaboration integrates Classiq’s cutting-edge engine within Wolfram Mathematica, offering a unified solution for the development of quantum and classical algorithms. This integration is targeted at enabling users to leverage the robust capabilities of Wolfram Mathematica for algorithm development and utilize Classiq’s Quantum Model (QMOD) language for quantum algorithm development—all within a single, cohesive environment. This blend of technologies empowers users to define, visualize and optimize quantum algorithms with unprecedented ease and efficiency. Key features of this collaboration are the facilitation of Classiq’s quantum algorithm compilation tailored to specific quantum hardware and ability to intricately develop quantum circuits from a high-level overview down to detailed gate operations. The integration further allows for the execution of these quantum circuits across a diverse array of backends and simulators, directly within the Mathematica notebook. This integration supports researchers by enhancing analytical capabilities, enabling continuous exploration and data assessment. As an example of the potential of this collaboration, the Quantum Differential Equations solver exemplifies how users will be able to tackle complex challenges by defining and executing quantum algorithms like the Harrow–Hassidim–Lloyd (HHL) algorithm and Quantum Singular Value Transformation (QSVT) for matrix inversion, directly from the Mathematica interface. This application highlights the power of combining classical computational methods with quantum processing to solve complex computational problems more efficiently. “The partnership between Classiq Technologies and Wolfram Research reflects a shared commitment to advancing computational excellence,” said Nir Minerbi, CEO of Classiq. “This collaboration not only enhances the toolset available for researchers and developers, we hope to see it pave the way for groundbreaking applications across various scientific and engineering disciplines.” "In the pursuit of applying quantum technologies to address real-world challenges, robust collaboration among industry leaders is paramount. We are delighted to unveil our strategic partnership with Classiq," remarked Mads Bahrami, quantum projects manager at Wolfram. "This partnership underscores the dedication of both entities towards crafting toolsets that empower governments, industries, and academia to tackle complex problems through quantum-classical algorithms." The companies invite those seeking to combine the best of quantum and classical computation to reach out and explore the possibilities this computation integration brings. About Wolfram Founded by Stephen Wolfram in 1987, Wolfram Research is one of the world's most respected computer, web and cloud software companies - as well as a powerhouse of scientific and technical innovation. As a pioneer in computation and computational knowledge, Wolfram has pursued a long-term vision to develop the science, technology and tools to make computation an ever-more-potent force in today's and tomorrow's world. As the creators of Mathematica, Wolfram|Alpha, the Wolfram Language, and Wolfram Quantum Framework, Wolfram is the leader in developing technology and tools that inject sophisticated computation and knowledge into everything. Wolfram's strategy as an organization is to maintain a portfolio of development, from continually strengthening core algorithms and the Wolfram Knowledgebase, to supporting the latest computing and deployment architectures, to developing major new concepts and capabilities - and consistently delivering the results in the form of products, services and experimental initiatives that make breakthrough technology accessible to the broadest possible spectrum of people and organizations. Learn more at: https://wolfr.am/QuantumConsulting https://www.wolfram.com/quantum-computation-framework/ Follow Wolfram on LinkedIn, X, and YouTube. Contact Wolfram quantum team: quantum@wolfram.com Contact Wolfram PR team: outreach@wolfram.com About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing platform (IDE, compiler and OS) with a single point of entry into quantum computing, taking you from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming. This ensures that a broad range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of quantum physics. Classiq democratizes access to quantum computing and equips its users to take full advantage of the quantum computing revolution, including access to a broad range of quantum hardware. Classiq's core technology - algorithmic quantum circuit compilation - is engineered to power the quantum ecosystem of today and the future. Classiq works closely with quantum cloud providers and advanced computation hardware developers providing software for use with quantum computers, HPC and quantum simulators. Backed by investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq's world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking quantum engine. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, and visit the Slack community and website, www.classiq.io to learn more. Contact Details Rainier Communications Michelle McMahon +1 781-718-3248 classiqPR@rainierco.com Company Website http://www.classiq.io/

April 23, 2024 08:00 AM Eastern Daylight Time

Capturing Consumer Spending on Health Care with XLV

Select Sector SPDR

With consumer spending on health care continuing to increase, the Health Care Select Sector SPDR Fund ( XLV ) provides an opportunity for investors to leverage this trend. XLV tracks health care stocks within the S&P 500 Index, offering broad exposure to core companies in the U.S. healthcare sector. The fund's top holdings* are comprised of market leaders across several sub-sectors of healthcare including companies such as Eli LIlly & Co (11.34%), Unitedhealth Group (8.36%), Johnson & Johnson (6.96%), Merck & Co (6.11%), AbbVie Inc. (5.87%), Thermo Fisher Scientific (4.10%), Abbott Laboratories (3.61%), Danaher Corp (3.00%), Pfizer (2.86%), and Amgen (2.78%). Growth Drivers in the Healthcare Sector As the health care sector continues to grow, these companies are well-positioned to benefit from increased consumer spending. The growth history in this sector has been driven by several factors, including a rise in chronic diseases, an aging population, and advancing medical technology. Total spending on health care rose from 16% of GDP in 2007 to an estimated 18% in 2023. Simultaneously, the total GDP has risen nearly 70% in that time, from 14.47 trillion in 2007 to 25.5 trillion in 2022. Investing in XLV offers a diversified way to capture steady consumer spending on health care. By investing in the health care market in a broad way, the ups and downs of a particular big name in the sector are mitigated by the exposure to other healthcare companies. DISCLAIMER: This is a work of research and should not be taken as investment or financial advice. Therefore, Select Sector SPDRs or the publisher is not liable for any decision made based on the publication. About the Company: Select Sector SPDR ETFs offer flexibility and customization opportunities. Many investors have similar outlooks, but no two are exactly alike. Select Sector SPDR ETFs let investors select the sectors that best meet their investment goals. *Holdings, Weightings & Assets as of 3/31/24 subject to change DISCLOSURES The S&P 500 Index is an unmanaged index of 500 common stocks that is generally considered representative of the U.S. stock market. The index is heavily weighted toward stocks with large market capitalizations and represents approximately two-thirds of the total market value of all domestic common stocks. The S&P 500 Index figures do not reflect any fees, expenses or taxes. An investor should consider investment objectives, risks, fees and expenses before investing. One may not invest directly in an index. Transparent ETFs provide daily disclosure of portfolio holdings and weightings All ETFs are subject to risk, including loss of principal. Sector ETF products are also subject to sector risk and nondiversification risk, which generally will result in greater price fluctuations than the overall market. Diversification does not eliminate risk. An investor should consider investment objectives, risks, charges and expenses carefully before investing. To obtain a prospectus, which contains this and other information, call 1-866-SECTOR-ETF (732-8673) or visit www.sectorspdrs.com. Read the prospectus carefully before investing. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is distributor for the Select Sector SPDR Trust. Media Contact: Company: Select Sector SPDRs Contact: Dan Dolan* Address: 1290 Broadway, Suite 1000, Denver, CO 80203 Country: United States Email: dan.dolan@sectorspdrs.com Website: https://www.sectorspdrs.com/ *Dan Dolan is a Registered Representative of ALPS Portfolio Solutions Distributor, Inc. ALPS Portfolio Solutions Distributor, Inc., a registered broker-dealer, is the distributor for the Select Sector SPDR Trust. SEL007449 EXP 5/31/24 Contact Details Dan Dolan +1 203-935-8103 dan.dolan@sectorspdrs.com Company Website https://www.sectorspdrs.com/

April 22, 2024 05:00 AM Eastern Daylight Time

Elsevier Appoints Dr Kieran West MBE as Executive Vice President of Strategy

Elsevier

Elsevier, a global leader in scientific information and analytics, announced today the appointment of Dr Kieran West MBE as Executive Vice President of Strategy, effective immediately. As an established senior executive with a track record of driving transformation and growth, Kieran joins Elsevier with extensive experience in healthcare, retail, consumer goods, and pharmaceuticals across international markets. Most recently, he served as Strategy Director at Bupa Global and UK, a leading healthcare provider and insurer, where he was instrumental in shaping the company's strategic direction. Prior to his time at Bupa, he served as an Associate Partner at McKinsey, where he advised both domestic and global companies on achieving commercial success. He previously taught mathematics at King’s College School, UK. His academic achievements include a PhD in History from the University of Cambridge, an MA in War Studies from King’s College London, and a PGCE degree in Mathematics. Kieran is also a world champion rower and Olympic gold-medallist, having won in the Men’s Eights in the 2000 Sydney Olympics. Kumsal Bayazit, CEO of Elsevier, said: “I am thrilled to welcome Kieran to Elsevier and look forward to the contribution that he will make with his strong strategic and operational experience, and his understanding of the healthcare, life sciences and academic communities. He is also passionate about developing individuals and delivering as a team, which is very much aligned with our values as an organization.” Kieran joins Elsevier’s Executive Leadership Team and will work across all areas of the company to develop and drive global strategic plans, including business development initiatives. He will be based in London. About Elsevier As a global leader in scientific information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies. We have supported the work of our research and healthcare communities for more than 140 years. Our 9,500 employees around the world, including 2,500 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 2,900 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation, we work in partnership with the communities we serve to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com. Contact Details Dan DiPietro-James +1 323-252-0645 Dan.james@elsevier.com

April 22, 2024 04:00 AM Eastern Daylight Time

UNOS unveils new artwork honoring organ donors and recipients

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) installed a mural by acclaimed artist Hamilton Glass to recognize the far-reaching impact of organ donation and to pay tribute to organ donors. The artwork is a Glass original, designed specifically for UNOS, and lives above the main entrance of UNOS’ headquarters in Richmond, Va. The mural portrays the interconnectedness of the organ donation and transplant community, with hands symbolizing the gesture of giving and receiving the gift of life. The blue ripples illustrate the ripple effect of donation on families and communities. “The artwork serves as a poignant reminder that every donation is a gift that touches us all, creating a network of support that UNOS tirelessly collaborates with daily to save lives,” said Glass. UNOS invited Richmond-based architect and artist Glass and his wife and business partner Taekia to design and create a piece of art that visually connects to and builds on the meaning of the National Donor Memorial. The memorial honors organ, eye and tissue donors and is open 24/7 to allow visitors to reflect on the journey of donation and transplant. “The lifesaving and lifechanging impact an organ donor has on both a recipient and their loved ones is incredibly profound, which is why we wanted to work with Hamilton Glass to create a piece of art that honors the selfless gifts organ donors provide,” said Maureen McBride, Ph.D., CEO of UNOS. “We want people to visit this mural and take in and learn how significant and impactful organ donation is.” Glass uses art to engage the public through big, bold designs and messages of hope, and has more than 300 murals on display throughout Richmond. The mural is approximately 16 feet tall and 40 feet wide and is comprised of 18 PVC panels. It is located on the exterior of UNOS’ building on North 4th Street in Richmond, Va. About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

April 19, 2024 03:54 PM Eastern Daylight Time

Image

Hydrogen Utopia CEO discusses advances in cannabis operation and future hydrogen projects

Hydrogen Utopia International PLC

Hydrogen Utopia International PLC (LSE:HUI, OTCQB:HUIPF) CEO Aleksandra Binkowska joined Proactive's Stephen Gunnion to discuss progress at the company’s cannabis operation in Macedonia, highlighting two successful harvests and ongoing developments. Binkowska noted the company has a 49% option in Ohrid Organics, highlighting its impressive facilities and high-tech enhancements, including an advanced drying system that significantly improves product quality. Binkowska emphasized the importance of the location’s natural benefits and technological enhancements for achieving high-quality outputs. Currently, Hydrogen Utopia is awaiting laboratory results to officially confirm the product quality, which is necessary for obtaining the requisite governmental paperwork for product sales. She mentioned preparations for EU GMP certification audits, which will facilitate entry into the European market at higher certification levels, potentially allowing for a higher product price point. Furthermore, Binkowska outlined the financial success of Ohrid Organics, projecting earnings that would fund Hydrogen Utopia’s first waste plastics hydrogen facility. The profits from Ohrid could potentially finance this without additional capital raising, underscoring the strategic advantage of the investment. She also highlighted the supportive role of the Macedonian government in facilitating the company's initiatives in both the cannabis and hydrogen sectors. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 18, 2024 08:40 AM Eastern Daylight Time

Video

CURE ALZHEIMER’S FUND REACHES $200 MILLION IN RESEARCH GRANTS

Alzheimer’s Disease Research Foundation

April 18, 2024 — Cure Alzheimer’s Fund, a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease, announced today that it has reached an important milestone—awarding more than $200 million in research grants to leading scientists throughout the world investigating the disease. Since its establishment in 2004, Cure Alzheimer’s Fund (CureAlz) has supported more than 840 innovative grants led by more than 300 scientists resulting in 1,182 published peer-reviewed papers in prominent scientific journals. Many of these projects have yielded significant breakthroughs, resulting in findings contributing to new and critical avenues for development of novel treatments. “CureAlz was founded with one mission: to fund research that will accelerate prevention, treatment and a cure for this disease,” said Henry McCance, Chair of Cure Alzheimer’s Fund. “Since the beginning, our approach has attracted others to join us in this fight, all who have been vital to what we have achieved. It has been an honor to deploy more than $200 million dollars in funding that is enabling and accelerating extraordinary research pursued by brilliant and determined scientists around the world.” Funded projects have included: · The Alzheimer’s Genome Project, the first large-scale, family-based study of the human genome specific to Alzheimer’s disease. · Projects that explore how the body’s complex immune responses may contribute to Alzheimer’s disease. · A consortium of experts to expand our understanding of the role the APOE gene may have in Alzheimer’s disease. “For 19 years, our Founders and Board of Directors have been steadfast in their commitment to our mission to end the terrible burden of Alzheimer’s. The field’s top scientists contribute their expertise and guidance to CureAlz, meaning science and data are always our lodestars to a cure,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Our leadership’s vision, drive and generosity are matched by that of our dedicated donor and researcher communities. We celebrate this milestone as the shared achievement it is, and at the same time rededicate ourselves to accelerating an end to Alzheimer’s.” Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided more than 840 grants to more than 300 of the world’s leading researchers and contributed more than $200 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. Our Board of Directors, Trustees, and a core group of other donors direct their donations to our overhead expenses so that 100% of general donations go to our research program. For more information, visit CureAlz.org. To learn about the impact of Alzheimer’s on women and women working towards a cure, WomenandAlzheimers.org. Contact Details Barbara Chambers +1 978-417-9890 BChambers@CureAlz.org Company Website https://curealz.org

April 18, 2024 08:00 AM Eastern Daylight Time

MJ ATTACHÉ LAUNCHES BUSINESS WITH DEBUT OF FIRST-OF-ITS-KIND LUXURY CACHE-AND-CARRY BAG FOR CANNABIS CONNOISSEURS, IN TIME FOR APRIL 20, CANNABIS CELEBRATION DAY

MJ Attaché

MJ Attaché, a designer and developer of luxury Italian-made leather bags and accessories for the cannabis connoisseur, announced today the official launch of the business. The commencement of MJ Attaché is marked by the introduction of the first-of-its-kind, premium, 100% Italian leather bag, The Anthony, carefully curated for cannabis cache and carry. The Anthony’s debut comes just in time for April 20 th, a day when cannabis is celebrated. MJ Attaché’s bags are market-disrupting; they boast patent-pending modular elements -- not found in any other bag -- that encourage a personalized cannabis experience specific to each one’s individual consumption needs. Catering to both male and female cannabis users, The Anthony’s novel magnetic, re-attachable accessories are fully customizable. Elements inside the bag can be easily added or deleted, depending on what each user prefers for their cannabis self-care ritual. Cleverly crafted by hand in Florence, Italy of the finest Italian leather, The Anthony’s features distinguish it from any other cannabis carry-all bag currently available in the market. Available in five colors, The Anthony bag includes a secure lock closure, removable smooth leather rolling tray, modular elements for customization, such as a pipe case, lighter sleeve, jar sleeve a smell-proof glass jar and a removable, adjustable crossbody strap. The combination of the leather and smell-proof jar aids in disguising odors and keep contents discreet. The MJ Attaché brand challenges outdated, inaccurate stereotypes of cannabis consumers by offering mainstream users a way to elevate their cache-and-carry preferences and experiences. Cannabis has come a long way from its prior perceptions, and MJ Attaché recognizes its broader adoption by users spanning the spectrum. Like many entrepreneurs, ideas are often spurred by personal experience. MJ Attaché is no exception. Founder Christy Fuicelli created the brand and designed its premium bag when she was personally searching for a sophisticated, safe and discreet carry-all solution for her cannabis and accessories. She came up emptyhanded when shopping for options of the same high-quality, sophistication and style to which she was accustomed. Fuicelli believed this void in the marketplace stemmed from stigmas associated with overall cannabis use and she set out to change the market landscape with the design, development and introduction of The Anthony. “I went on a crusade to create a stylish, luxury, handcrafted bag many would be proud to carry. With its impeccable style, quality Italian leather components and customizable modular system, The Anthony bag transcends the outdated “stoner” stereotypes cannabis users are often perceived as and creates the ultimate luxury cannabis experience. I travelled on this journey witnessing nearly a dozen iterations of The Anthony until I was pleased because I could not find a functional, sophisticated, stylish and well-made cannabis transport option, which sparked my interest in developing one myself,” entrepreneur Fuicelli said. “Additionally, I was determined to challenge preconceived notions relating to cannabis use stereotypes. Many people use cannabis medicinally as well as to reduce stress and anxiety and promote relaxation. For me, my cannabis use not only helped alleviate certain medical conditions but also can be directly attributed to the deep creativity it ignited in me, sparking my idea for The Anthony and other bags and accessories in the MJ Attaché product line. I am hoping adoption of The Anthony and other MJ Attaché offerings will simplify the lives of cannabis users around the world. The Anthony truly marks an entry into a market where no other bag like it exists,” Fuicelli concluded. The Anthony, with a price point of $2,150.00, can be purchased here. Looking ahead, MJ Attaché is currently developing other cannabis bag styles and accessories, which are slated for introduction into the marketplace in the latter part of 2024. About MJ Attaché Denver-based MJ Attaché is a designer and developer of high-quality, handmade Italian leather bags and accessories for the cannabis connoisseur. The luxury brand, with its moniker MJ (short for Mary Jane an alias for marijuana), was founded by entrepreneur Christy Fuicelli, a stylish cannabis user. She realized a void in the marketplace to cache and carry her cannabis in a discreet manor reflective of the luxury she enjoyed in other personal products she owned and believed this stemmed from stigmas associated with cannabis use. Determined to bridge this gap, MJ Attaché was born. Fuicelli set out to create a premium bag that would appeal to both male and female cannabis users. She spent years designing and creating beautifully crafted bags that embody elevated style, sophistication, high quality and fine craftmanship. By bringing ease and style to the cannabis industry with her bags, MJ Attaché brings the first accessory of its kind, The Anthony bag, to the marketplace. For more information, visit www.mjattache.com and connect with the Company and its products on Facebook and Instagram. Contact Details PAIRELATIONS, LLC for MJ Attaché Susan J. Turkell +1 303-766-4343 sturkell@pairelations.com

April 17, 2024 10:00 AM Eastern Daylight Time

Image

Clarified Precision Medicine Raises $1.2 Million in Seed Funding and Appoints Health Tech Leader Rajni Natesan, MD, MBA as CEO

Clarified Precision Medicine

Clarified Precision Medicine, the only company that provides oncologists with prioritized therapy options via a combination of algorithmic testing and physician oversight, announced that it closed on its seed round of $1.2 million led by Avestria Ventures, with participation from Joyance Partners, both early-stage funds focused on improving health. The company also named Rajni Natesan, MD, MBA as its Chief Executive Officer. Dr. Natesan is an experienced executive and medical doctor with an extensive background scaling startups at the intersection of healthcare and technology, with a focus on artificial intelligence and machine learning. “Clarified Precision Medicine is offering the right technology at the right time,” Dr. Natesan said. “I’m excited to guide Clarified through this period of commercialization and growth as we follow through on our mission to provide any patient, anywhere, with cutting-edge, guidelines-based access to precision medicine.” Founded in 2021 by Dr. Lincoln Nadauld, MD, PhD, Lisa Alderson, MBA, Howard McLeod, PharmD, and Jody Simon, PharmD, Clarified Precision Medicine uses an algorithm to analyze NGS lab results and then works with oncologists to interpret genomic test results to recommend the best targeted treatment. I n the United States, there are 18 million patients with a history of cancer and 1.9 million new cancer diagnoses each year. Patients who receive precision therapies have survival rates that are three times greater than those who do not. However, 75 percent of doctors say they need help interpreting genomic tests—which leads to more effective utilization of these powerful 21-century tools. Clarified’s combination of advanced technology and physician oversight provides oncologists at community cancer centers with the precision treatment knowledge and expertise usually reserved for leading research institutions. “Dr. Natesan is the perfect leader to help us scale Clarified Precision Medicine to ensure that oncology practices across the country have access to expert guidance to deliver improved outcomes,” said Clarified Precision Medicine Co-founder Lisa Alderson. “She has the right combination of business acumen and clinical expertise to drive adoption and engage with key stakeholders to make world-class precision medicine expertise accessible to every cancer patient and every oncology practice. We’re excited to support Dr. Natesan as she leads us into the next chapter of growth.” With deep C-suite expertise in finance, strategy, operations and clinical functions across medical devices and health tech, Dr. Natesan has led companies across all phases of their product and organizational life cycles, from conceptual design to FDA trials, commercialization, IP and M&A preparation. Dr. Natesan began her career as one of the first physicians on Wall Street, leading health care mergers, acquisitions and financing deals for pharma, biotech and med device clients as an investment banker in Lehman Brothers’ health care group and as a health care strategy consultant in a boutique practice. Most recently, Dr. Natesan served as Chief Strategy and Medical Officer at Braid Health, a venture-backed, disruptive digital health infrastructure company. Clarified Precision Medicine is already supporting numerous U.S. oncology practices and testing labs and offers flexible payment options, including direct insurance billing in some cases. More information on Clarified Precision Medicine solutions is available from the Clarified Precision Medicine Business Development team. About Clarified Precision Medicine Clarified Precision Medicine is the first scalable molecular tumor board with a combination of ML-based platform plus medical group, offering expert clinical somatic and pharmacogenomics consultations through its ClarifiedSelect™ and OncoGuardian™ solutions. Clarified accelerates the delivery of guidelines-based genomic insights to patients and providers by bringing together nationally recognized experts in medical oncology, oncology pharmacy, data integration, and molecular pathology who have over 100 years of collective experience in the application of precision oncology. For more information, visit: www.clarifiedprecisionmedicine.com Contact Details For Clarified Precision Medicine info@clarifiedmedicine.com Company Website https://clarifiedprecisionmedicine.com/

April 16, 2024 10:09 AM Eastern Daylight Time

1 ... 7 8 9 10 11 ... 163